|
|
.
NPI Detail
NPI: 1538164090
Type: Organization
Taxonomy Code: 251E00000X
Home Health Agency
Agencies/Home Health
1924 XXXXX XXX
KNOXVILLE, TN 379201511
Business phone: (XXX) XXX-XXXX
Mailing address phone: (XXX) XXX-XXXX
|
Click here for new NPI search.
|
2021 OPPS Part A Medicare Services Submitted NPI-1538164090*
OPPS Payment Method "A" - Services not paid under OPPS; uses a different fee schedule (e.g., ambulance, PT, mammography)
Top Level I HCPC Procedures
| Procedure | Description | Number Submitted | Medicare Payment |
| 80053
|
COMPREHEN METABOLIC PANEL
|
XXXXX
|
$XXXXX.X
|
| 85025
|
COMPLETE CBC W/AUTO DIFF WBC
|
XXXXX
|
$XXXXX.XX
|
Top Drugs Administered Other than Oral Method
| Procedure | Description | Number Submitted | Medicare Payment |
| J1439
|
Inj ferric carboxymaltos 1mg
|
XXXXXX
|
$XXXXXX.XX
|
| J0881
|
Darbepoetin alfa, non-esrd
|
XXXXXX
|
$XXXXXX.XX
|
| J9299
|
Injection, nivolumab
|
XXXXXX
|
$XXXXXXX.XX
|
| J9271
|
Inj pembrolizumab
|
XXXXXX
|
$XXXXXXX.XX
|
| J1453
|
Fosaprepitant injection
|
XXXXXX
|
$XXXXX.XX
|
| J0897
|
Denosumab injection
|
XXXXXX
|
$XXXXXXX.XX
|
| J1447
|
Inj tbo filgrastim 1 microg
|
XXXXX
|
$XXXXX.XX
|
| J9267
|
Paclitaxel injection
|
XXXXX
|
-
|
| J9263
|
Oxaliplatin
|
XXXXX
|
-
|
| J9176
|
Injection, elotuzumab, 1mg
|
XXXXX
|
$XXXXXX.XX
|
| J9119
|
Inj., cemiplimab-rwlc, 1 mg
|
XXXXX
|
$XXXXXXX.XX
|
| J0585
|
Injection,onabotulinumtoxina
|
XXXXX
|
$XXXXXX.XX
|
| J9025
|
Azacitidine injection
|
XXXXX
|
$XXXXX.XX
|
| J9306
|
Injection, pertuzumab, 1 mg
|
XXXXX
|
$XXXXXX.XX
|
| J1100
|
Dexamethasone sodium phos
|
XXXXX
|
-
|
| J9035
|
Bevacizumab injection
|
XXXXX
|
$XXXXXXX.XX
|
| J9171
|
Docetaxel injection
|
XXXXX
|
-
|
| J0878
|
Daptomycin injection
|
XXXXX
|
-
|
| J0875
|
Injection, dalbavancin
|
XXXXX
|
$XXXXXX.XX
|
| J9264
|
Paclitaxel protein bound
|
XXXXX
|
$XXXXXX.XX
|
| J9022
|
Inj, atezolizumab,10 mg
|
XXXXX
|
$XXXXXXX.XX
|
| J0256
|
Alpha 1 proteinase inhibitor
|
XXXXX
|
$XXXXX.XX
|
| J0885
|
Epoetin alfa, non-esrd
|
XXXXX
|
$XXXXXX.XX
|
| J3380
|
Injection, vedolizumab
|
XXXXX
|
$XXXXXX.XX
|
| J9312
|
Inj., rituximab, 10 mg
|
XXXXX
|
$XXXXXXX.XX
|
| J3262
|
Tocilizumab injection
|
XXXXX
|
$XXXXX.XX
|
| J9144
|
Daratumumab, hyaluronidase
|
XXXXX
|
$XXXXXX.XX
|
| J1569
|
Gammagard liquid injection
|
XXXXX
|
$XXXXXX.XX
|
| J9145
|
Injection, daratumumab 10 mg
|
XXXXX
|
$XXXXXX.XX
|
| J2469
|
Palonosetron hcl
|
XXXXX
|
-
|
| J9355
|
Inj trastuzumab excl biosimi
|
XXXXX
|
$XXXXXXX.XX
|
| J0896
|
Inj luspatercept-aamt 0.25mg
|
XXXXX
|
$XXXXXX.XX
|
| J9034
|
Inj., bendeka 1 mg
|
XXXXX
|
$XXXXXX.XX
|
| J9311
|
Inj rituximab, hyaluronidase
|
XXXXX
|
$XXXXXX.XX
|
Top HCPC Level II Procedures / Professional Services
| Procedure | Description | Number Submitted | Medicare Payment |
| G0463
|
Hospital outpt clinic visit
|
XXXXX
|
$XXXXXXX.XX
|
| G0378
|
Hospital observation per hr
|
XXXXX
|
-
|
* Medicare Part A utilization data is derived from the 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
|
